Well said. When it comes to efficacy on what will be the first indication for Leronlimab and the first major legitamizer (probably not a word but it’s way to early for me to care) for Leronlimab and Cytodyn, it doesn’t matter when it just matters that it happens. That will mean the world to our investments, and also help save lives. Today or ten days from now isn’t all that important. Beating placebo is. Today’s call did us all a huge favor. It removed the doubt that we could see a failure in the M to M trial based on knowing that these patients typically already get better on their own. Now I’m no longer nervous. It’s there. We “beat placebo” in at least a few very important areas so far. Based on that information there should be more endpoints hit as well. Until the day they drop the full results on the world, what better indicators can we get about our chances than that?